Conclusion:
Currently Nine trials (Table-2) on Remdesivir are ongoing to evaluate
its safety and efficacy in the treatment of Covid 19. Results of these
clinical trials will provide crucial information about whether
remdesivir represents a viable treatment option for COVID-19 . While
there is limited information known about the safety and effectiveness of
using remdesivir to treat people in the hospital with COVID-19, the
investigational drug was shown in clinical trial to shorten the time to
recovery in some patients.[16] If the trial
findings are ultimately positive, it will be imperative to ensure that
the drug is produced on a commercial scale capable of meeting the demand
generated by both the current pandemic and future outbreaks.
References:
- Center for Health Security. The characteristics of pandemic
pathogens.cited Mar 4, 2019. Available from:http://www.centerforhealth
security.org/our-work/pubs_archive/pubs-pdfs/2018/180510-pandemic-pathogens-report.pdf.
- R.N. Kirchdoerfer, A.B. Ward, Structure of the SARS-CoV nsp12
polymerase bound to nsp7 and nsp8 co-factors, Nat. Commun. 10 (1)
(2019) 2342,
- Cj G, Ep T, Jy F, et al. The antiviral compound remdesivir potently
inhibits RNAdependent RNA polymerase from Middle East respiratory
syndrome coronavirus. J Biol Chem 2020.
- E. de Wit, F. Feldmann, J. Cronin, R. Jordan, A. Okumura, T. Thomas,
et al., Prophylactic and therapeutic remdesivir (GS-5734) treatment in
the rhesus macaque model of MERS-CoV infection, Proc. Natl. Acad. Sci.
U. S. A. (2020),
- Sheahan TP, Sims AC, Leist SR, Schäfer A, Won J, Brown AJ et al.
Comparative therapeutic efficacy of remdesivir and combination
lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat
Commun. 2020:10;11(1):222.
- B.G. Murphy, M. Perron, E. Murakami, K. Bauer, Y. Park, C. Eckstrand,
et al., The nucleoside analog GS-441524 strongly inhibits feline
infectious peritonitis (FIP) virus in tissue culture and experimental
cat infection studies, Vet. Microbiol. 2018;219: 226–233
- N.C. Pedersen, M. Perron, M. Bannasch, E. Montgomery, E. Murakami, M.
Liepnieks, et al., Efficacy and safety of the nucleoside analog
GS-441524 for treatment of cats with naturally occurring feline
infectious peritonitis, J. Feline Med. Surg. 2019; 21(4): 271–81
- Lo MK, Feldmann F, Gary JM, Jordan R, Bannister R, Cronin J et al.
Remdesivir (GS-5734) protects African green monkeys from Nipah virus
challenge. Sci Transl Med. 2019; 29;11(494). pii: eaau9242
- Lo MK, Jordan R, Arvey A, Sudhamsu J, Shrivastava-Ranjan P, Hotard AL
et al. GS-5734 and its parent nucleoside analog inhibit Filo-,
Pneumo-, and Paramyxoviruses. Sci Rep. 2017;7:43395
- Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively
inhibit the recently emerged novel coronavirus (2019-nCoV) in
vitro. Cell Res . 2020;30(3):269‐71
- Levine MM. Monoclonal Antibody Therapy for Ebola Virus Disease. N Engl
J Med 2019; 381:2365-6
- Mulangu S, Dodd LE, Davey RT Jr, Tshiani Mbaya O, Proschan M, Mukadi D
et al. A Randomized, Controlled Trial of Ebola Virus Disease
Therapeutics. N Engl J Med. 2019;381(24):2293-303
- Jacobs M, Rodger A, Bell DJ, Bhagani S, Cropley I, Filipe A, et al.
Late Ebola virus relapse causing meningoencephalitis: a case report.
Lancet. 2016;338: 498–503
- Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe
COVID-19: a randomised, double-blind, placebo-controlled, multicentre
trial.Lancet .2020;395:1569-78
- Gilead Announces Results From Phase 3 Trial of Investigational
Antiviral Remdesivir in Patients with Severe COVID-19 [news
release]. Foster City, CA; April 29, 2020: Gilead Sciences.
- US Food & Drug Administration (FDA). Coronavirus (COVID-19) Update:
FDA Issues Emergency Use Authorization for Potential COVID-19
Treatment. FDA News Release. 1st May 2020.
(https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-emergency-use-authorization-potential-covid-19-treatment)
- “Summary on Compassionate Use: Remdesivir Gilead”
(https://www.ema.europa.eu/en/documents/other/summary-compassionate-use-remdesivir-gilead_en.pdf)
(PDF). European Medicines Agency. Retrieved 1 May 2020
- Warren TK, Jordan R, Lo MK, Ray AS, Mackman RL, Soloveva V et al.
Therapeutic efficacy of the small molecule GS-5734 against Ebola virus
in rhesus monkeys. Nature. 2016;531(7594):381-5
- Summaries of evidence from selected experimental therapeutics. 2018 as
of October
https://www.who.int/ebola/drc-2018/summaries-of-evidenceexperimental-
therapeutics.pdf?ua=1